Prothena Corp. Plc(NASDAQ : PRTA)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-7.41%||11.87||0.7%||$829.76m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.48%||188.60||1.9%||$536.66m|
|GILD||Gilead Sciences, Inc.||-0.42%||67.07||1.0%||$495.93m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.08%||534.67||2.7%||$388.70m|
|ALXN||Alexion Pharmaceuticals, Inc.||-0.56%||179.65||2.0%||$338.01m|
|TXG||10X Genomics, Inc.||0.28%||198.43||0.0%||$177.84m|
|EXAS||EXACT Sciences Corp.||0.65%||128.49||18.1%||$177.55m|
Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firmâ€™s clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimerâ€™s disease, Parkinsonâ€™s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.